Influence of obesity on localized prostate cancer patients treated with radical prostatectomy

Asian Journal of Andrology

Volumn 15, Issue 6, 2013, Pages 747-752

  Qu, Yuan Yuan ^a,b   Dai, Bo ^a,b   Kong, Yun Yi ^a,b   Chang, Kun ^a,b   Ye, Ding Wei ^a,b   Yao, Xu Dong ^a,b   Zhang, Shi Lin ^a,b   Zhang, Hai Liang ^a,b   Yang, Wei Yi ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

body mass index (BMI); obesity; prostatic neoplasm; radical prostatectomy; testosterone; visceral adiposity

Indexed keywords

TESTOSTERONE;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY MASS; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE; SUBCUTANEOUS FAT;

AGED; BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84887232649     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2013.104     Document Type: Article

References (30)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009-2010. NCHS Data Brief 2012; (82): 1-8.
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 2003; 348: 1625-38. (Pubitemid 36459468)
3. Buschemeyer WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331-43. (Pubitemid 46963472)
4. Loeb S, Yu X, Nadler RB, Roehl KA, Han M et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007; 177: 102-6. (Pubitemid 44895330)
5. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001; 58: 723-8.
6. Boorjian SA, Crispen PL, Carlson RE, Rangel LJ, Karnes RJ et al. Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy. J Endourol 2008; 22: 1471-6.
7. Castle EP, Atug F, Woods M, Thomas R, Davis R. Impact of body mass index on outcomes after robot assisted radical prostatectomy. World J Urol 2008; 26: 91-5.
8. Motamedinia P, Korets R, Spencer BA, Benson MC, McKiernan JM. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology 2008; 72: 1106-10.
9. Campeggi A, Xylinas E, Ploussard G, Ouzaid I, Fabre A et al. Impact of body mass index on perioperative morbidity, oncological, and functional outcomes after extraperitoneal laparoscopic radical prostatectomy. Urology 2012; 80: 576-84.
10. Isbarn H, Jeldres C, Budäus L, Salomon G, Schlomm T et al. Effect of body mass index on histopathologic parameters: results of large European contemporary consecutive open radical prostatectomy series. Urology 2009; 73: 615-9.
11. Briganti A, Karakiewicz PI, Chun FK, Suardi N, Gallina A et al. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. Int J Urol 2009; 16: 676-81.
12. Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F et al. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population? BJU Int 2009; 103: 877-82.
13. Zhu Y, Wang HK, Zhang HL, Yao XD, Zhang SL et al. Visceral obesity and risk of high grade disease in clinical T1a renal cell carcinoma. J Urol 2013; 189: 447-53.
14. Rick AS, Iannuzzi JC, Mironov O, Deeb AP, Sharma A et al. Visceral obesity and colorectal cancer: are we missing the boat with BMI? J Gastrointest Surg 2013; 17: 133-43.
15. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V et al. Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 2010; 22: 281-8.
16. von Hafe P, Pina F, Perez A, Tavares M, Barros H. Visceral fat accumulation as a risk factor for prostate cancer. Obes Res 2004; 12: 1930-5.
17. Rohrmann S, Shiels MS, Lopez DS, Rifai N, Nelson WG et al. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control 2011; 22: 1141-51.
18. Derby CA, Zilber S, Brambilla D, Morales KH, McKinlay JB. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006; 65: 125-31.
19. Dai B, Qu YY, Kong YY, Ye DW, Yao XD et al. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer. BJU Int 2012; 110: E667-72.
20. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009; 55: 121-30.
21. Mucksavage P, Mitchell C, Kutikov A, Wein AJ, Torigian D et al. Anthropometric differences in obese men with biochemical failure after radical retropubic prostatectomy. Urol Oncol 2012; 30: 590-5.
22. World Health Organization, Western Pacific Region, International Association for the Study of Obesity. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia Pty Limited; 2000.
23. Pischon T, Boeing H, Weikert S, Allen N, Key T et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2008; 17: 3252-61.
24. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC et al. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev 2011; 20: 844-53.
25. Hoon Kim J, Lee SY, Myung SC, Kim YS, Kim TH et al. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J Androl 2008; 10: 923-8.
26. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F et al. A prospective study of plasma-hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26: 40-9.
27. Freedland SJ, Platz EA. Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97. (Pubitemid 47229642)
28. Häheim LL, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-74. (Pubitemid 44522081)
29. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nature Reviews Urology 2011; 8: 483-94.
30. Morote J, Ropero J, Planas J, Bastaró s JM, Delgado G et al. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int 2013; 111: 1031-6.